New York, NY -- (SBWIRE) -- 12/24/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Glu Mobile Inc (NASDAQ:GLUU), Rexahn Pharmaceuticals, Inc (NYSEMKT:RNN), Generex Biotechnology Corporation (OTCMKTS:GNBT),
Glu Mobile Inc (NASDAQ:GLUU) showed a volume of 3.73 million shares by the end of last trade whereas the average volume of the stock remained 2.42 million shares. The stock opened the session at $3.93 but then moved to $4.08. At that price, the stock showed a positive performance of 4.62%. Glu Mobile Inc. (Glu) designs, markets and sells mobile games. The Company has developed and published a portfolio of action/adventure and casual games designed to appeal to a cross section of the users of smartphones and tablet devices who purchase its games through direct-to-consumer digital storefronts, as well as users of feature phones served by wireless carriers and other distributors. It creates games based on its own original brands, as well as third-party licensed brands. Its original games include Big Time Gangsta, Blood & Glory, Bug Village,
Will GLUU Continue To Move Higher? Find Out Here
Rexahn Pharmaceuticals, Inc (NYSEMKT:RNN) opened the session at $0.44 and closed the session at $0.475. The stock showed a positive performance of 10.77% in previous trading session. Traded with volume of 2.72 million shares in the prior session and the average volume of the stock remained 1.26 million shares. Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company’s pipeline features one drug candidate in Phase II clinical trials. The Company also has several other drug candidates in pre-clinical development. In addition, the Company has two renal cell carcinoma (CNS) candidates, Serdaxin,
For How Long RNN will fight for Profitability? Read This Trend Analysis report
Generex Biotechnology Corporation (OTCMKTS:GNBT) opened the session at $0.03 and closed the session at $0.0295. The stock showed a negative performance of -1.01% in previous trading session. Traded with volume 1.94 million shares in the prior session and the average volume of the stock remained 1.92 million shares. The beta of the stock remained 2.13. Generex Biotechnology Corporation is a Canada-based Company, which develops drug delivery systems and technologies for the treatment of diabetes. The Company has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity. Its buccal insulin spray product, Generex Oral-lyn is in Phase III clinical trials at several sites around the world. The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist device.
Why Should Investors Buy GNBT After the Recent Fall? Just Go Here and Find Out
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)